Search
Showing results for "lung disease preterm"
In Perth, The Kids Research Institute Australia is spearheading global efforts to tackle this insidious bacterium and reduce its impact on kids’ health.
Australia has nothing to lose by voting Yes, but First Nations people have everything to gain. And if the lives of First Nations people improve, we all win.
The minimum number of doses of pneumococcal conjugate vaccine required for protection is not known. We studied the immunogenicity of a reduced schedule in...
Type 1 diabetes is a chronic autoimmune disease that results from the immune system attacking the insulin-producing cells of the pancreas. Unlike type 2 diabetes which is potentially preventable, type 1 is a non-preventable disease - currently, its exact cause is not known and there is no cure.
The END RHD CRE focuses priority research projects that will help achieve the singular target of producing the Endgame Strategy.
The Sore Throat Study is looking for healthy children and young people to take part in a new study investigating sore throats, also known as pharyngitis, and how best to prevent them.
END RHD is an alliance of health, research and community organisations seeking to amplify efforts to end rheumatic heart disease in Australia through advocacy and engagement.
The overarching goal of the Australian coronavirus disease 2019 (COVID-19) vaccination program has been to protect all people in Australia from the harm caused by the novel coronavirus SARS-CoV-2. This review reflects on the role of the Australian Technical Advisory Group on Immunisation (ATAGI) in the national COVID-19 vaccination program, in terms of the initial programmatic and clinical recommendations in the evolving context of evidence relating to the disease and vaccines, epidemiology, and the program rollout.
Acute rheumatic fever (ARF), a serious inflammatory condition, often leads to rheumatic heart disease. Between 2011 and 2016, Aotearoa New Zealand implemented a rheumatic fever prevention programme to reduce high rates of ARF through improved community access to timely diagnosis and early treatment of group A streptococcal pharyngitis, which has been shown to prevent subsequent ARF.
Invasive Group B Streptococcus remains a leading cause of infant morbidity and mortality. Intrapartum antibiotic prophylaxis has been implemented in many countries with a reduction in early-onset disease, but an effective vaccine may further reduce the disease burden. Candidate vaccines targeting capsular polysaccharides and surface proteins are now in clinical trials.